Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo.

Tulic MK, Cavazza E, Cheli Y, Jacquel A, Luci C, Cardot-Leccia N, Hadhiri-Bzioueche H, Abbe P, Gesson M, Sormani L, Regazzetti C, Beranger GE, Lereverend C, Pons C, Khemis A, Ballotti R, Bertolotto C, Rocchi S, Passeron T.

Nat Commun. 2019 May 16;10(1):2178. doi: 10.1038/s41467-019-09963-8.

2.

Nicotinamide as a chemopreventive therapy of skin cancers. Too much of good thing?

Ballotti R, Healy E, Bertolotto C.

Pigment Cell Melanoma Res. 2019 Jul;32(4):601-602. doi: 10.1111/pcmr.12772. Epub 2019 Feb 27. No abstract available.

PMID:
30742742
3.

[Key role of nicotinamide phosphoribosyltransferase (NAMPT) and NAD metabolism in the transition of melanoma cells to an invasive and drug-resistant phenotype].

Bertolotto C, Ohanna M, Ballotti R.

Med Sci (Paris). 2018 Dec;34(12):1025-1028. doi: 10.1051/medsci/2018283. Epub 2019 Jan 9. French. No abstract available.

PMID:
30623759
4.

Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma.

Wiedemann GM, Aithal C, Kraechan A, Heise C, Cadilha BL, Zhang J, Duewell P, Ballotti R, Endres S, Bertolotto C, Kobold S.

Transl Oncol. 2019 Feb;12(2):350-360. doi: 10.1016/j.tranon.2018.10.014. Epub 2018 Nov 28.

5.

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.

Garandeau D, Noujarède J, Leclerc J, Imbert C, Garcia V, Bats ML, Rambow F, Gilhodes J, Filleron T, Meyer N, Brayer S, Arcucci S, Tartare-Deckert S, Ségui B, Marine JC, Levade T, Bertolotto C, Andrieu-Abadie N.

Mol Cancer Ther. 2019 Feb;18(2):289-300. doi: 10.1158/1535-7163.MCT-17-1141. Epub 2018 Nov 27.

PMID:
30482853
6.

Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells.

Leclerc J, Garandeau D, Pandiani C, Gaudel C, Bille K, Nottet N, Garcia V, Colosetti P, Pagnotta S, Bahadoran P, Tondeur G, Mograbi B, Dalle S, Caramel J, Levade T, Ballotti R, Andrieu-Abadie N, Bertolotto C.

Oncogene. 2019 Feb;38(8):1282-1295. doi: 10.1038/s41388-018-0500-0. Epub 2018 Sep 25.

PMID:
30254208
7.

E2F1 inhibition mediates cell death of metastatic melanoma.

Rouaud F, Hamouda-Tekaya N, Cerezo M, Abbe P, Zangari J, Hofman V, Ohanna M, Mograbi B, El-Hachem N, Benfodda Z, Lebeau A, Tulic MK, Hofman P, Bertolotto C, Passeron T, Annicotte JS, Ballotti R, Rocchi S.

Cell Death Dis. 2018 May 1;9(5):527. doi: 10.1038/s41419-018-0566-1.

8.

Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.

Ohanna M, Cerezo M, Nottet N, Bille K, Didier R, Beranger G, Mograbi B, Rocchi S, Yvan-Charvet L, Ballotti R, Bertolotto C.

Genes Dev. 2018 Mar 1;32(5-6):448-461. doi: 10.1101/gad.305854.117. Epub 2018 Mar 22.

9.

Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells.

El-Hachem N, Habel N, Naiken T, Bzioueche H, Cheli Y, Beranger GE, Jaune E, Rouaud F, Nottet N, Reinier F, Gaudel C, Colosetti P, Bertolotto C, Ballotti R.

Cell Death Differ. 2018 Nov;25(11):2010-2022. doi: 10.1038/s41418-018-0090-y. Epub 2018 Mar 7.

PMID:
29515254
10.

Deregulated MITF sumoylation: A route to melanoma.

Ballotti R, Bertolotto C.

Mol Cell Oncol. 2017 May 26;4(4):e1331154. doi: 10.1080/23723556.2017.1331154. eCollection 2017.

11.

Pathways from senescence to melanoma: focus on MITF sumoylation.

Leclerc J, Ballotti R, Bertolotto C.

Oncogene. 2017 Nov 30;36(48):6659-6667. doi: 10.1038/onc.2017.292. Epub 2017 Aug 21. Review.

PMID:
28825724
12.

Focus on cutaneous and uveal melanoma specificities.

Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C.

Genes Dev. 2017 Apr 15;31(8):724-743. doi: 10.1101/gad.296962.117. Review.

13.

Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.

Bonet C, Luciani F, Ottavi JF, Leclerc J, Jouenne FM, Boncompagni M, Bille K, Hofman V, Bossis G, Marco de Donatis G, Strub T, Cheli Y, Ohanna M, Luciano F, Marchetti S, Rocchi S, Birling MC, Avril MF, Poulalhon N, Luc T, Hofman P, Lacour JP, Davidson I, Bressac-de Paillerets B, Ballotti R, Marine JC, Bertolotto C.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw340.

PMID:
28376192
14.

FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells.

Bourseguin J, Bonet C, Renaud E, Pandiani C, Boncompagni M, Giuliano S, Pawlikowska P, Karmous-Benailly H, Ballotti R, Rosselli F, Bertolotto C.

Sci Rep. 2016 Nov 9;6:36539. doi: 10.1038/srep36539.

15.

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

Richard G, Dalle S, Monet MA, Ligier M, Boespflug A, Pommier RM, de la Fouchardière A, Perier-Muzet M, Depaepe L, Barnault R, Tondeur G, Ansieau S, Thomas E, Bertolotto C, Ballotti R, Mourah S, Battistella M, Lebbé C, Thomas L, Puisieux A, Caramel J.

EMBO Mol Med. 2016 Oct 4;8(10):1143-1161. doi: 10.15252/emmm.201505971. Print 2016 Oct.

16.

Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.

Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, Botton T, Ronco C, Abbe P, Amdouni H, Passeron T, Hofman V, Mograbi B, Dabert-Gay AS, Debayle D, Alcor D, Rabhi N, Annicotte JS, Héliot L, Gonzalez-Pisfil M, Robert C, Moréra S, Vigouroux A, Gual P, Ali MMU, Bertolotto C, Hofman P, Ballotti R, Benhida R, Rocchi S.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.007. Epub 2016 Jul 11. No abstract available.

17.

Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.

Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, Botton T, Ronco C, Abbe P, Amdouni H, Passeron T, Hofman V, Mograbi B, Dabert-Gay AS, Debayle D, Alcor D, Rabhi N, Annicotte JS, Héliot L, Gonzalez-Pisfil M, Robert C, Moréra S, Vigouroux A, Gual P, Ali MMU, Bertolotto C, Hofman P, Ballotti R, Benhida R, Rocchi S.

Cancer Cell. 2016 Jun 13;29(6):805-819. doi: 10.1016/j.ccell.2016.04.013. Epub 2016 May 26. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

18.

NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.

De Donatis GM, Le Pape E, Pierron A, Cheli Y, Hofman V, Hofman P, Allegra M, Zahaf K, Bahadoran P, Rocchi S, Bertolotto C, Ballotti R, Passeron T.

Oncogene. 2016 May;35(21):2813. doi: 10.1038/onc.2015.468. No abstract available.

PMID:
27225420
19.

Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P; French Familial Melanoma Study Group, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B.

Nature. 2016 Mar 3;531(7592):126. doi: 10.1038/nature16158. Epub 2015 Dec 2. No abstract available.

PMID:
26633630
20.

NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.

De Donatis GM, Le Pape E, Pierron A, Cheli Y, Hofman V, Hofman P, Allegra M, Zahaf K, Bahadoran P, Rocchi S, Bertolotto C, Ballotti R, Passeron T.

Oncogene. 2016 May;35(21):2735-45. doi: 10.1038/onc.2015.331. Epub 2015 Sep 14. Erratum in: Oncogene. 2016 May;35(21):2813.

PMID:
26364600
21.

NF1 loss induces senescence during human melanocyte differentiation in an iPSC-based model.

Larribere L, Wu H, Novak D, Galach M, Bernhardt M, Orouji E, Weina K, Knappe N, Sachpekidis C, Umansky L, Beckhove P, Umansky V, De Schepper S, Kaufmann D, Ballotti R, Bertolotto C, Utikal J.

Pigment Cell Melanoma Res. 2015 Jul;28(4):407-16. doi: 10.1111/pcmr.12369. Epub 2015 Apr 22.

PMID:
25824590
22.

Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib.

Lehraiki A, Cerezo M, Rouaud F, Abbe P, Allegra M, Kluza J, Marchetti P, Imbert V, Cheli Y, Bertolotto C, Ballotti R, Rocchi S.

Cell Discov. 2015 Oct 27;1:15030. doi: 10.1038/celldisc.2015.30. eCollection 2015.

23.

Molecular phylogeny, species limits, and biogeography of the Brazilian endemic lizard genus Enyalius (Squamata: Leiosauridae): an example of the historical relationship between Atlantic Forests and Amazonia.

Rodrigues MT, Bertolotto CE, Amaro RC, Yonenaga-Yassuda Y, Freire EM, Pellegrino KC.

Mol Phylogenet Evol. 2014 Dec;81:137-46. doi: 10.1016/j.ympev.2014.07.019. Epub 2014 Sep 16.

PMID:
25234242
24.

CD271 is an imperfect marker for melanoma initiating cells.

Cheli Y, Bonnazi VF, Jacquel A, Allegra M, De Donatis GM, Bahadoran P, Bertolotto C, Ballotti R.

Oncotarget. 2014 Jul 30;5(14):5272-83.

25.

Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma.

Fernández-Barral A, Orgaz JL, Baquero P, Ali Z, Moreno A, Tiana M, Gómez V, Riveiro-Falkenbach E, Cañadas C, Zazo S, Bertolotto C, Davidson I, Rodríguez-Peralto JL, Palmero I, Rojo F, Jensen LD, del Peso L, Jiménez B.

Neoplasia. 2014 Jun;16(6):529-42. doi: 10.1016/j.neo.2014.06.001. Epub 2014 Jul 13.

26.

Inhibition of melanogenesis by the antidiabetic metformin.

Lehraiki A, Abbe P, Cerezo M, Rouaud F, Regazzetti C, Chignon-Sicard B, Passeron T, Bertolotto C, Ballotti R, Rocchi S.

J Invest Dermatol. 2014 Oct;134(10):2589-2597. doi: 10.1038/jid.2014.202. Epub 2014 Apr 22.

27.

SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells.

Ohanna M, Bonet C, Bille K, Allegra M, Davidson I, Bahadoran P, Lacour JP, Ballotti R, Bertolotto C.

Oncotarget. 2014 Apr 30;5(8):2085-95.

28.

Melanoma: from melanocyte to genetic alterations and clinical options.

Bertolotto C.

Scientifica (Cairo). 2013;2013:635203. doi: 10.1155/2013/635203. Epub 2013 Dec 12. Review.

29.

Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.

Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S, Bille K, Bahadoran P, Giacchero D, Lacour JP, Boyle GM, Hayward NF, Bertolotto C, Ballotti R.

Oncotarget. 2013 Dec;4(12):2212-24.

30.

A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.

Allegra M, Giacchero D, Segalen C, Dumaz N, Butori C, Hofman V, Hofman P, Lacour JP, Bertolotto C, Bahadoran P, Ballotti R.

J Invest Dermatol. 2014 May;134(5):1473-1476. doi: 10.1038/jid.2013.525. Epub 2013 Dec 6. No abstract available.

31.

A germline oncogenic MITF mutation and tumor susceptibility.

Paillerets BB, Lesueur F, Bertolotto C.

Eur J Cell Biol. 2014 Jan-Feb;93(1-2):71-5. doi: 10.1016/j.ejcb.2013.10.002. Epub 2013 Oct 26. Review.

PMID:
24290354
32.

PGJ2 restores RA sensitivity in melanoma cells by decreasing PRAME and EZH2.

Pierron A, Le Pape E, Montaudié H, Castela E, De Donatis GM, Allegra M, Bertolotto C, Rocchi S, Cheli Y, Ballotti R, Passeron T.

J Dermatol Sci. 2014 Mar;73(3):258-61. doi: 10.1016/j.jdermsci.2013.11.003. Epub 2013 Nov 11. No abstract available.

PMID:
24289988
33.

Metabolism under the spotlight in senescence.

Bertolotto C.

Pigment Cell Melanoma Res. 2014 Jan;27(1):3-5. doi: 10.1111/pcmr.12184. Epub 2013 Nov 1. No abstract available.

PMID:
24125180
34.

Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.

Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S.

Mol Cancer Ther. 2013 Aug;12(8):1605-15. doi: 10.1158/1535-7163.MCT-12-1226-T. Epub 2013 Jun 5.

35.

Autophagy plays a critical role in the degradation of active RHOA, the control of cell cytokinesis, and genomic stability.

Belaid A, Cerezo M, Chargui A, Corcelle-Termeau E, Pedeutour F, Giuliano S, Ilie M, Rubera I, Tauc M, Barale S, Bertolotto C, Brest P, Vouret-Craviari V, Klionsky DJ, Carle GF, Hofman P, Mograbi B.

Cancer Res. 2013 Jul 15;73(14):4311-22. doi: 10.1158/0008-5472.CAN-12-4142. Epub 2013 May 23.

36.

Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.

Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, Bahadoran P, Rocchi S, Ballotti R, Bertolotto C.

J Biol Chem. 2012 Aug 24;287(35):29887-98. doi: 10.1074/jbc.M112.371682. Epub 2012 Jul 5.

37.

[MITF: a genetic key to melanoma and renal cell carcinoma?].

Bertolotto C, Lesueur F, Bressac de Paillerets B.

Med Sci (Paris). 2012 Mar;28(3):258-61. doi: 10.1051/medsci/2012283010. Epub 2012 Apr 6. French. No abstract available.

38.

Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

Passeron T, Lacour JP, Allegra M, Ségalen C, Deville A, Thyss A, Giacchero D, Ortonne JP, Bertolotto C, Ballotti R, Bahadoran P.

Exp Dermatol. 2011 Dec;20(12):1030-2. doi: 10.1111/j.1600-0625.2011.01385.x.

PMID:
22092579
39.

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P; French Familial Melanoma Study Group, Aubin F, Bachollet B, Becuwe C, Berthet P, Bignon YJ, Bonadona V, Bonafe JL, Bonnet-Dupeyron MN, Cambazard F, Chevrant-Breton J, Coupier I, Dalac S, Demange L, d'Incan M, Dugast C, Faivre L, Vincent-Fétita L, Gauthier-Villars M, Gilbert B, Grange F, Grob JJ, Humbert P, Janin N, Joly P, Kerob D, Lasset C, Leroux D, Levang J, Limacher JM, Livideanu C, Longy M, Lortholary A, Stoppa-Lyonnet D, Mansard S, Mansuy L, Marrou K, Matéus C, Maugard C, Meyer N, Nogues C, Souteyrand P, Venat-Bouvet L, Zattara H, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B.

Nature. 2011 Oct 19;480(7375):94-8. doi: 10.1038/nature10539. Erratum in: Nature. 2016 Mar 3;531(7592):126.

PMID:
22012259
40.

Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells.

Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, Bahadoran P, Lacour JP, Tartare-Deckert S, Bertolotto C, Ballotti R.

Oncogene. 2012 May 10;31(19):2461-70. doi: 10.1038/onc.2011.425. Epub 2011 Sep 26.

PMID:
21996743
41.

Metformin inhibits melanoma development through autophagy and apoptosis mechanisms.

Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, Tartare-Deckert S, Bahadoran P, Auberger P, Ballotti R, Rocchi S.

Cell Death Dis. 2011 Sep 1;2:e199. doi: 10.1038/cddis.2011.86.

42.

GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells.

Javelaud D, Alexaki VI, Pierrat MJ, Hoek KS, Dennler S, Van Kempen L, Bertolotto C, Ballotti R, Saule S, Delmas V, Mauviel A.

Pigment Cell Melanoma Res. 2011 Oct;24(5):932-43. doi: 10.1111/j.1755-148X.2011.00893.x. Epub 2011 Aug 18.

PMID:
21801332
43.

Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS).

Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, Bille K, Robert C, Bressac-de Paillerets B, Hofman P, Rocchi S, Peyron JF, Lacour JP, Ballotti R, Bertolotto C.

Genes Dev. 2011 Jun 15;25(12):1245-61. doi: 10.1101/gad.625811. Epub 2011 Jun 6.

44.

Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.

Bourcier C, Griseri P, Grépin R, Bertolotto C, Mazure N, Pagès G.

Am J Physiol Cell Physiol. 2011 Sep;301(3):C609-18. doi: 10.1152/ajpcell.00506.2010. Epub 2011 May 18.

45.

BRCA1 is a new MITF target gene.

Beuret L, Ohanna M, Strub T, Allegra M, Davidson I, Bertolotto C, Ballotti R.

Pigment Cell Melanoma Res. 2011 Aug;24(4):725-7. doi: 10.1111/j.1755-148X.2011.00862.x. Epub 2011 May 13. No abstract available.

PMID:
21501420
46.

Novel pathway of adipogenesis through cross-talk between adipose tissue macrophages, adipose stem cells and adipocytes: evidence of cell plasticity.

Chazenbalk G, Bertolotto C, Heneidi S, Jumabay M, Trivax B, Aronowitz J, Yoshimura K, Simmons CF, Dumesic DA, Azziz R.

PLoS One. 2011 Mar 31;6(3):e17834. doi: 10.1371/journal.pone.0017834.

47.

Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.

Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, Hofman P, Bahadoran P, Bertolotto C, Ballotti R.

Oncogene. 2011 May 19;30(20):2307-18. doi: 10.1038/onc.2010.598. Epub 2011 Jan 31. Erratum in: Oncogene. 2011 May 19;30(20):2390. Guiliano, S [corrected to Giuliano, S].

PMID:
21278797
48.

Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma.

Strub T, Giuliano S, Ye T, Bonet C, Keime C, Kobi D, Le Gras S, Cormont M, Ballotti R, Bertolotto C, Davidson I.

Oncogene. 2011 May 19;30(20):2319-32. doi: 10.1038/onc.2010.612. Epub 2011 Jan 24.

PMID:
21258399
49.

Advances in melanoma senescence and potential clinical application.

Giuliano S, Ohanna M, Ballotti R, Bertolotto C.

Pigment Cell Melanoma Res. 2011 Apr;24(2):295-308. doi: 10.1111/j.1755-148X.2010.00820.x. Epub 2011 Jan 11. Review.

PMID:
21143770
50.

Fitting MITF regulation of PDE4D3 into the skin pigmentation puzzle.

Ohanna M, Bertolotto C, Ballotti R.

Pigment Cell Melanoma Res. 2011 Feb;24(1):4-6. doi: 10.1111/j.1755-148X.2010.00795.x. No abstract available.

PMID:
21040501

Supplemental Content

Loading ...
Support Center